FDA Fails to Approve Pfizer's Biosimilar of Roche's Herceptin

Pfizer Inc. (NYSE:PFE) announced on 4/23/18  that it received a Complete Response Letter (CRL) from the FDA in response to the Biologics License Application for the company’s proposed trastuzumab biosimilar.